Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
109,628,845
-
Total 13F shares
-
43,406,257
-
Share change
-
-104,498
-
Total reported value
-
$140,608,833
-
Put/Call ratio
-
240%
-
Price per share
-
$3.24
-
Number of holders
-
109
-
Value change
-
+$5,128,346
-
Number of buys
-
52
-
Number of sells
-
65
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) as of Q3 2024
As of 30 Sep 2024,
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) was held by
109 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,406,257 shares.
The largest 10 holders included
TCG Crossover Management, LLC, VANGUARD GROUP INC, BlackRock, Inc., PERCEPTIVE ADVISORS LLC, Alyeska Investment Group, L.P., 683 Capital Management, LLC, Almitas Capital LLC, abrdn plc, CITADEL ADVISORS LLC, and ACADIAN ASSET MANAGEMENT LLC.
This page lists
107
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.